PubRank

Stephen A Beers

Author PubWeight™ 18.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006 3.59
2 Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011 1.91
3 Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009 1.76
4 Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood 2013 1.58
5 Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 2011 1.44
6 Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2009 1.38
7 Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011 1.34
8 Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem 2008 1.15
9 FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother 2013 0.90
10 Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. Arthritis Rheum 2011 0.85
11 Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol 2013 0.80
12 Complement: help or hindrance? Blood 2009 0.79
13 Therapeutic (high) doses of rituximab activate calcium mobilization and inhibit B-cell growth via an unusual mechanism triggered independently of both CD20 and Fcgamma receptors. J Immunother 2010 0.78
14 FcγRIIB as a key determinant of agonistic antibody efficacy. Curr Top Microbiol Immunol 2014 0.77